|Dr. Barry D. Quart||Pres, CEO & Director||1.18M||6.05M||1957|
|Mr. Robert E. Hoffman CPA, CPA||CFO & Sr. VP of Fin.||579.93k||686.23k||1966|
|Mr. John W. Poyhonen||Exec. VP, Chief Commercial Officer & Director||62.5k||N/A||1960|
|Ms. Kimberly J. Manhard||Exec. VP of Drug Devel. & Director||825.14k||624.56k||1960|
|Mr. David L. Szekeres||Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec.||N/A||N/A||1974|
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 1; Compensation: 9.